List view / Grid view
As a promising treatment for type 2 diabetes and obesity,…
As a promising treatment for type 2 diabetes and obesity, based on key trial data, the market for glucagon-like peptide-1 receptor (GLP-1R) therapies looks set to generate major sales up to 2030.
Once-weekly or once-monthly dosing of Mim8 provides optionality and flexibility…
Once-weekly or once-monthly dosing of Mim8 provides optionality and flexibility for people living with haemophilia A with or without inhibitors, stated Novo Nordisk’s EVP for Development.
The up to €1bn acquisition of Cardior Pharmaceuticals will strengthen…
The up to €1bn acquisition of Cardior Pharmaceuticals will strengthen Novo Nordisk’s pipeline in cardiovascular disease.
The new data suggests Novo Nordisk’s small molecule treatment semaglutide…
The new data suggests Novo Nordisk’s small molecule treatment semaglutide could become the first GLP-1 treatment option for patients with type 2 diabetes and chronic kidney disease (CKD).
Novo Nordisk has set its sights on acquiring a medicine…
Novo Nordisk has set its sights on acquiring a medicine with best-in-class potential for hypertension from KBP Biosciences.
Under a $1 billion acquisition agreement, Novo Nordisk A/S will…
Under a $1 billion acquisition agreement, Novo Nordisk A/S will investigate a potential first-in-class small molecule CB1 receptor blocker as a treatment for obesity.
In Novo Nordisk’s landmark trial for cardiovascular outcomes, semaglutide 2.4mg…
In Novo Nordisk’s landmark trial for cardiovascular outcomes, semaglutide 2.4mg has potential to change how obesity is regarded and treated, headline data suggests.
Ziltivekimab was found to reduce inflammatory biomarkers of atherosclerosis by…
Ziltivekimab was found to reduce inflammatory biomarkers of atherosclerosis by up to 93 percent in patients with chronic kidney disease and high cardiovascular risk.
